Literature DB >> 16731611

Reply to "IHC for Her2 with CBE356 antibody is a more accurate predictor of Her2 gene amplification by FISH than HercepTest in breast carcinoma".

K Egervari, Z Szollosi, Z Nemes.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16731611      PMCID: PMC1860406     

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


× No keyword cloud information.
  4 in total

1.  A real-time one-step reverse transcriptase-polymerase chain reaction method to quantify c-erbB-2 expression in human breast cancer.

Authors:  V Pawlowski; F Révillion; L Hornez; J P Peyrat
Journal:  Cancer Detect Prev       Date:  2000

2.  Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification.

Authors:  A D Seidman; M N Fornier; F J Esteva; L Tan; S Kaptain; A Bach; K S Panageas; C Arroyo; V Valero; V Currie; T Gilewski; M Theodoulou; M E Moynahan; M Moasser; N Sklarin; M Dickler; G D'Andrea; M Cristofanilli; E Rivera; G N Hortobagyi; L Norton; C A Hudis
Journal:  J Clin Oncol       Date:  2001-05-15       Impact factor: 44.544

3.  IHC for Her2 with CBE356 antibody is a more accurate predictor of Her2 gene amplification by FISH than HercepTest in breast carcinoma.

Authors:  R Ainsworth; J M S Bartlett; J J Going; E A Mallon; A Forsyth; J Richmond; W Angerson; A Watters; B Dunne
Journal:  J Clin Pathol       Date:  2005-10       Impact factor: 3.411

4.  Reliability of the tissue microarray based FISH for evaluation of the HER-2 oncogene in breast carcinoma.

Authors:  D Gancberg; A Di Leo; G Rouas; T Järvinen; A Verhest; J Isola; M J Piccart; D Larsimont
Journal:  J Clin Pathol       Date:  2002-04       Impact factor: 3.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.